Bioinformatics and Integrative Experimental Method to Identifying and Validating Co-Expressed Ferroptosis-Related Genes in OA Articular Cartilage and Synovium
Jinxin Ma,Peng Yu,Shang Ma,Jinjin Li,Zhen Wang,Kunpeng Hu,Xinzhe Su,Bei Zhang,Shao Cheng,Shangzeng Wang
DOI: https://doi.org/10.2147/jir.s434226
IF: 4.5
2024-02-13
Journal of Inflammation Research
Abstract:Jinxin Ma, 1, &ast Peng Yu, 1, &ast Shang Ma, 1, &ast Jinjin Li, 1 Zhen Wang, 1 Kunpeng Hu, 1 Xinzhe Su, 1 Bei Zhang, 1 Shao Cheng, 1– 3 Shangzeng Wang 1– 3 1 School of Osteopathy, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China; 2 Department of Arthropathy, Henan Province Hospital of Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou, People's Republic of China; 3 School of Osteopathy, Henan Province Engineering Research Center of Basic and Clinical Research of Bone and Joint Repair in Chinese Medicine, Zhengzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shao Cheng; Shangzeng Wang, 156 Jinshui East Road, Zhengzhou, Henan, People's Republic of China, Tel +86 15093141825 ; +86 13838527504, Fax +0371-86667366, Email ; Purpose: Osteoarthritis (OA) is the most common joint disease worldwide and is the primary cause of disability and chronic pain in older adults.Ferroptosis is a type of programmed cell death characterized by aberrant iron metabolism and reactive oxygen species accumulation; however, its role in OA is not known. Methods: To identify ferroptosis markers co-expressed in articular cartilage and synovium samples from patients with OA, in silico analysis was performed.Signature genes were analyzed and the results were evaluated using a ROC curve prediction model.The biological function, correlation between Signature genes, immune cell infiltration, and ceRNA network analyses were performed. Signature genes and ferroptosis phenotypes were verified through in vivo animal experiments and clinical samples. The expression levels of non-coding RNAs in samples from patients with OA were determined using qRT-PCR. ceRNA network analysis results were confirmed using dual-luciferase assays. Results: JUN, ATF3, and CDKN1A were identified as OA- and ferroptosis-associated signature genes. GSEA analysis demonstrated an enrichment of these genes in immune and inflammatory responses, and amino acid metabolism. The CIBERSORT algorithm showed a negative correlation between T cells and these signature genes in the cartilage, and a positive correlation in the synovium. Moreover, RP5-894D12.5 and FAM95B1 regulated the expression of JUN, ATF3, and CDKN1A by competitively binding to miR-1972, miR-665, and miR-181a-2-3p. In vivo, GPX4 was downregulated in both OA cartilage and synovium; however, GPX4 and GSH were downregulated, while ferrous ions were upregulated in patient OA cartilage and synovium samples, indicating that ferroptosis was involved in the pathogenesis of OA. Furthermore, JUN, ATF3, and CDKN1A expression was downregulated in both mouse and human OA synovial and cartilage tissues. qRT-PCR demonstrated that miR-1972, RP5-894D12.5, and FAM95B1 were differentially expressed in OA tissues. Targeted interactions between miR-1972 and JUN, and a ceRNA regulatory mechanism between RP5-894D12.5, miR-1972, and JUN were confirmed by dual-luciferase assays. Conclusion: This study identified JUN, ATF3, and CDKN1A as possible diagnostic biomarkers and therapeutic targets for joint synovitis and OA. Furthermore, our finding indicated that RP5-894D12.5/miR-1972/JUN was a potential ceRNA regulatory axis in OA, providing an insight into the connection between ferroptosis and OA. Keywords: osteoarthritis, ferroptosis, synovitis, bioinformatics, JUN, ATF3, CDKN1A, GPX4 Osteoarthritis (OA) is a degenerative joint disease that primarily affects elderly individuals and causes articular cartilage morphology changes, destroys cartilage, and leads to osteophyte formation. 1 It has a high incidence and disability rate and is characterized by joint pain, swelling, and stiffness; thus, it exerts a great burden on both individuals and society. By 2021, OA was estimated to affect approximately 300 million people worldwide, 2 and it ranked sixth in Asia and eleventh globally in terms of years of disability. 3 Early diagnosis and treatment of OA can effectively improve patients' quality of life, delay progression, and reduce the financial burden on patients' families and national healthcare systems. OA is a complex disease caused by multiple factors, including aging, obesity, sex, overuse, trauma, joint deformity, and genetic susceptibility. 4,5 The release of proinflammatory cytokines plays a critical role in synovial inflammation and cartilage matrix destruction, which lead to degradation and destructive responses in articular cartilage, thus contributing to the progression of OA. 6 In 2012, Dix -Abstract Truncated-
immunology